Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A...

Area of Science:

• Genetics
• Oncology
• Bioinformatics

Background:

• Germline variants contribute significantly to prostate cancer (PrCa) risk.
• Few heritable factors are linked to PrCa clinical progression.

Purpose of the Study:

• Identify rare germline variants predicting time to biochemical recurrence (BCR) post-treatment in PrCa.
• Elucidate genetic factors associated with PrCa progression.

Main Methods:

• Whole-genome sequencing of blood DNA from 850 PrCa patients (PPCG consortium).
• Validation in 383 patients from The Cancer Genome Atlas (TCGA).
• Analysis of 15,822 rare, predicted-deleterious coding germline mutations using Cox regression models.

Main Results:

• Rare deleterious germline variants in specific gene sets (PI3K/AKT/mTOR, Inflammatory response, KRAS signalling) associate with altered BCR time.
• Associations were observed in higher-grade cancers and validated in independent datasets (e.g., Hypoxia).

Conclusions:

• Rare deleterious coding germline variants are robustly associated with time to BCR post-treatment.
• Germline testing at diagnosis may aid in stratifying PrCa patients for tailored clinical management.